VAV2, a guanine nucleotide exchange factor for Rac1, regulates glucose-stimulated insulin secretion in pancreatic beta cells
- 1.5k Downloads
Rho GTPases (Ras-related C3 botulinum toxin substrate 1 [Rac1] and cell division cycle 42 [Cdc42]) have been shown to regulate glucose-stimulated insulin secretion (GSIS) via cytoskeletal remodelling, trafficking and fusion of insulin-secretory granules with the plasma membrane. GTP loading of these G proteins, which is facilitated by GDP/GTP exchange factors, is a requisite step in the regulation of downstream effector proteins. Guanine nucleotide exchange factor VAV2 (VAV2), a member of the Dbl family of proteins, has been identified as one of the GDP/GTP exchange factors for Rac1. Despite recent evidence on the regulatory roles of VAV2 in different cell types, roles of this guanine nucleotide exchange factor in the signalling events leading to GSIS remain undefined. Using immunological, short interfering RNA (siRNA), pharmacological and microscopic approaches we investigated the role of VAV2 in GSIS from islet beta cells.
Co-localisation of Rac1 and VAV2 was determined by Triton X-114 phase partition and confocal microscopy. Glucose-induced actin remodelling was quantified by live cell imaging using the LifeAct-GFP fluorescent biosensor. Rac1 activation was determined by G protein linked immunosorbent assay (G-LISA).
Western blotting indicated that VAV2 is expressed in INS-1 832/13 beta cells, normal rat islets and human islets. Vav2 siRNA markedly attenuated GSIS in INS-1 832/13 cells. Ehop-016, a newly discovered small molecule inhibitor of the VAV2–Rac1 interaction, or siRNA-mediated knockdown of VAV2 markedly attenuated glucose-induced Rac1 activation and GSIS in INS-1 832/13 cells. Pharmacological findings were recapitulated in primary rat islets. A high glucose concentration promoted co-localisation of Rac1 and VAV2. Real-time imaging in live cells indicated a significant inhibition of glucose-induced cortical actin remodelling by Ehop-016.
Our data provide the first evidence to implicate VAV2 in glucose-induced Rac1 activation, actin remodelling and GSIS in pancreatic beta cells.
KeywordsCytoskeleton Insulin secretion Pancreatic islet Rac1 VAV2
Cell division cycle 42
Guanine nucleotide exchange factor
Green fluorescent protein
Glucose-stimulated insulin secretion
G protein linked immunosorbent assay
Ras-related C3 botulinum toxin substrate 1
Src family of tyrosine kinases
Short interfering RNA
T-lymphoma invasion and metastasis-inducing protein 1
Guanine nucleotide exchange factor VAV2
Insulin secretion from pancreatic beta cells is principally regulated by ambient glucose concentrations. However, potential cellular mechanisms underlying the stimulus–secretion coupling of glucose-stimulated insulin secretion (GSIS) are only partially understood. GSIS occurs largely via the generation of soluble second messengers, such as cyclic nucleotides and biologically active lipids, as well as an increase in intracellular calcium concentrations [1, 2, 3, 4].
Small G proteins (Ras-related C3 botulinum toxin substrate 1 [Rac1] and cell division cycle 42 [Cdc42]) play key regulatory roles in cytoskeletal remodelling to promote mobilisation of secretory granules to the plasma membrane for fusion and the release of their cargo into circulation [5, 6, 7]. Published evidence affirms the involvement of Cdc42, Rac1 and Arf6 in GSIS [5, 6, 7, 8, 9, 10, 11]. Functional activation–deactivation of these G proteins is modulated by a variety of regulatory factors/proteins. At least three classes of such factors/proteins have been described, including: (1) guanine nucleotide exchange factors (GEFs), which facilitate the conversion of GDP-bound (inactive) forms of G proteins to their GTP-bound (active) forms; (2) GDP-dissociation inhibitors (GDIs), which prevent the dissociation of GDP from G proteins, and hence are considered inhibitory in the G protein activation cascade; and (3) GTPase activating proteins, which promote the conversion of the GTP-bound, functionally active G proteins to their respective GDP-bound inactive conformation by activating the intrinsic GTPase activity of candidate G proteins to complete the activation–deactivation cycle . Several recent studies have identified and studied GEFs for Cdc42, Rac1 and Arf6, which are implicated in GSIS. They include T-lymphoma invasion and metastasis-inducing protein 1 (Tiam1), Rho guanine nucleotide exchange factor 7 (Cool-1/βPIX) and cytohesin-2 (ARNO), which have been shown to increase GTP loading onto Rac1, Cdc42 and Arf6, respectively [6, 10, 12, 13]. Furthermore, Rho-GDI has been shown to regulate Cdc42 and Rac1 signalling pathways in islet beta cells, leading to GSIS [14, 15].
In addition to Tiam1 (a GEF for Rac1), guanine nucleotide exchange factor VAV2 (VAV2) has been identified as a GEF in the regulation of Rac1 functions in many cell types [16, 17, 18]. VAV2 belongs to the mammalian Vav family of GEFs: Vav1 is exclusively expressed only in haematopoietic cells , whereas VAV2 and VAV3 are ubiquitously expressed . VAV2 is relatively unstudied. In general, there is little information on its role in cellular function; in particular, its expression levels and role in regulating GSIS have not been examined in islet beta cells. Several domains that span the VAV2 protein are important for various signalling events and also exhibit tyrosine-phosphorylation-dependent GEF activity [20, 21, 22]. Several Src family tyrosine kinases (SFKs) such as Lck and Fyn [23, 24], Syk family tyrosine kinases (Syk and Zap70) [24, 25], and receptor tyrosine kinases [26, 27] have been implicated as mediators of VAV2 tyrosine phosphorylation. Recent studies have shown that activation of tyrosine-protein kinase Yes (an Src family kinase) is indispensable for Cdc42 activation in a glucose-specific manner in pancreatic beta cells . The aim of the current study, therefore, was to understand the roles of VAV2 in islet function, including GSIS. We addressed this by quantifying GSIS in beta cells in which VAV2 expression was suppressed via a short interfering RNA (siRNA) approach. Findings from these experiments were further validated by a pharmacological approach involving Ehop-016, a novel small molecule inhibitor of VAV2–Rac1 interaction (electronic supplementary material [ESM] Fig. 1) . Collectively, findings from these investigations implicate VAV2, and perhaps the glucose-induced tyrosine phosphorylation of VAV2, in the process of Rac1-mediated cortical actin remodelling and GSIS.
Antisera against VAV2 and β-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Sigma-Aldrich (St Louis, MO, USA), respectively. Enhanced chemiluminescence kits were obtained from Amersham Biosciences (Piscataway, NJ, USA). Rac1 antiserum was obtained from BD Transduction Laboratories (San Jose, CA, USA). Donkey anti-mouse Alexa Fluor 488 and donkey anti-rabbit Alexa Fluor 568 conjugated secondary antibodies were obtained from Life technologies (Grand Island, NY, USA). The rat insulin ELISA kit was obtained from American Laboratory Products Co (Windham, NH, USA). The G protein linked immunosorbent assay (G-LISA) kit used for the Rac1 activation assay was obtained from Cytoskeleton (Denver, CO, USA). Vav2 siRNA and scrambled siRNA were obtained from Thermo Scientific (Waltham, MA, USA). Ehop-016 was synthesised as previously described . SU6656 was obtained from Calbiochem (San Diego, CA, USA).
INS-1 832/13 cells, rat islets and human islets
INS-1 832/13 cells were cultured as previously described [8, 10]. Islets from normal male Sprague Dawley rats (∼6 weeks old; Harlan Laboratories, Oxford, MI, USA) were isolated by the collagenase digestion method [8, 10]. All protocols were reviewed and approved by the Institutional Animal Care and Use Committee at Wayne State University. Human islets were obtained from PRODO Laboratories (Irvine, CA, USA). Studies involving human islets were conducted according to the guidelines established by the US Department of Health and Human Services/NIH and approved by the Biosafety Committee at the John D. Dingell VA Medical Center.
Insulin release assay
INS-1 832/13 cells or rat islets were incubated overnight with either vehicle or Ehop-016 (5 μmol/l) in low glucose (LG; 2.5 mmol/l) and low serum (LS; 2.5%) medium. Following a 60 min pre-incubation in KRB, the cells were further stimulated with either LG (2.5 mmol/l) or high glucose (HG; 20 mmol/l) for 45 min at 37°C with or without Ehop-016. Insulin released was quantified by ELISA [8, 10].
Transfection studies with siRNA
INS-1 832/13 cells were transfected with ON-TARGETplus SMARTpool Vav2 siRNA or scrambled siRNA at a final concentration of 80 nmol/l using Lipofectamine RNAiMAX transfection reagent (Life technologies, Grand Island, NY, USA). The efficiency of VAV2 knockdown was determined by western blot analysis at 48 h post-transfection.
Rac1 activation assay
Activated Rac1 was quantified by the Rac1 activation G-LISA assay kit in INS-1 832/13 cells treated with Ehop-016 or transfected with Vav2 siRNA .
Live cell imaging studies
INS-1 832/13 cells were seeded on MatTek (Ashland, MA, USA) glass bottom culture dishes at a density of 400,000 cells per 35 mm dish. At ∼50% confluency, cells were transfected with the LifeAct-GFP plasmid using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) . Live cell imaging was performed on cells at 48 h post-transfection. Briefly, cells were pre-incubated overnight in LS-LG medium with or without Ehop-016 (5 μmol/l). After 24 h, cells were pre-incubated in KRB buffer for 1 h with or without Ehop-016. Images were captured every 2 min, starting from 0–20 min after the addition of 20 mmol/l glucose .
Subcellular fractionation: Triton X-114 phase partitioning assay
Lysates derived from INS-1 832/13 cells treated with LG or HG were centrifuged at 100,000g for 60 min at 4°C to obtain total membrane (pellet) and soluble (supernatant) fractions. The hydrophilic and hydrophobic phases of the total membrane fractions were isolated using Triton X-114 as previously described .
VAV2–Rac1 co-localisation by confocal immunofluorescence microscopy
INS-1 832/13 cells were plated on glass coverslips. After 24 h, the cells were incubated in LS-LG medium overnight and then with KRB for 1 h prior to incubation with LG or HG for 15 min at 37°C. Following this, cells were washed in PBS, fixed in ice-cold methanol for 20 min at −20°C and then washed in PBS. Non-specific binding sites were first blocked for 1 h with 5% donkey serum and then cells were incubated with mouse anti-Rac1 monoclonal antibody (1:200 dilution) for 1 h, washed, and then incubated overnight with rabbit anti-VAV2 polyclonal antibody (1:100 dilution). After washing in PBS, cells were incubated for 1 h with Alexa Fluor 488 to detect Rac1. To detect VAV2, cells were incubated with Alexa Fluor 568. PBS with 5% donkey serum was used for antibody dilution. Cells were then washed and proteins were visualised by confocal scanning laser microscopy, as previously described .
The statistical significance of differences between control and experimental conditions was determined by the Student’s t test and ANOVA. A p value of <0.05 was considered statistically significant.
VAV2 is expressed in INS-1 832/13 cells, rodent and human islets and regulates GSIS
Ehop-016 attenuates GSIS from INS-1 832/13 cells and normal rodent islets
Inhibition of VAV2 suppresses glucose-induced Rac1 activation in INS-1 832/13 cells
A large number of studies have demonstrated that GSIS involves activation of Arf6, Cdc42 and Rac1, with these activation events being necessary steps for the cytoskeletal remodelling to facilitate the movement of granules from the intracellular location towards the plasma membrane [5, 6, 7]. Since VAV2 is a known regulator of Rac1 [18, 19, 20], we next asked whether glucose-induced activation of Rac1 is sensitive to inhibition of VAV2. To address this, we quantified glucose-induced Rac1 activation in INS-1 832/13 cells incubated in the absence or presence of Ehop-016. Data in Fig. 2c indicate a significant increase in Rac1 activation by stimulatory concentrations of glucose. Furthermore, Ehop-016 completely inhibited glucose-induced activation of Rac1 under these conditions, without significantly affecting basal levels of Rac1 activation (Fig. 2c). Furthermore, we noticed significant inhibition of glucose-induced Rac1 activation following siRNA-mediated knockdown of VAV2 (Fig. 2d). Collectively, our findings in INS-1 832/13 cells and normal rodent islets suggest that GSIS involves an activation step involving VAV2 that is upstream of Rac1 activation.
We also assessed the regulatory roles of VAV2 in KCl-induced insulin secretion in INS-1 832/13 cells, and observed that KCl-induced insulin secretion is modestly inhibited by Ehop-016 (ESM Fig. 2). More importantly, unlike stimulatory glucose (Fig. 2d), KCl failed to activate Rac1 (ESM Fig. 2) in both control and Vav2 siRNA transfected cells (ESM Fig. 2). Even though Rac1 activity was lower than under basal conditions (i.e. control cells treated with LG) in cells transfected with scrambled and Vav2 siRNA, this was not due to decreased levels of Rac1 in these cells (additional data not shown). These observations are compatible with previous observations that Rac1 activation is dispensable for KCl-induced insulin secretion [6, 8].
Glucose promotes the association between VAV2 and Rac1: evidence from Triton X-114 phase partition assay and immunofluorescence methods
The VAV2–Rac1 axis mediates glucose-induced filamentous actin (F-actin) remodelling in beta cells
SU6656, a tyrosine kinase inhibitor, attenuates glucose-induced phosphorylation of VAV2 in beta cells
The main objective of this study was to investigate the role of VAV2, a known GEF for Rac1, in GSIS. Our findings suggest that the molecular biological and pharmacological inhibition of VAV2 results in the inhibition of glucose-induced activation of Rac1 and GSIS in INS-1 832/13 cells and primary rodent islets, thus suggesting novel roles for VAV2–Rac1 signalling in GSIS. It is well established that Cdc42 and Rac1 play essential roles in cytoskeletal remodelling, vesicular transport and fusion with the plasma membrane [5, 6]. Using a variety of experimental approaches, we previously described regulatory roles for Rac1 in islet function and GSIS [6, 8, 36, 37, 38]. We demonstrated that inhibition of Rac1 function significantly attenuated glucose-, but not KCl-induced insulin secretion in clonal beta cells and rodent islets [8, 38]. We also reported that pharmacological or molecular biological inhibition of Tiam1, a known GEF for Rac1, significantly inhibits GSIS . These data suggested that Tiam1 is one of the GEFs involved in glucose-induced activation of Rac1 and insulin secretion.
What then are the roles of VAV2 in this signalling cascade? Our current findings clearly raise an interesting possibility that other GEFs, such as VAV2, regulate GSIS. It is likely that both Tiam1 and VAV2 exert distinct regulatory functions leading to the activation of Rac1 and downstream signalling steps, including activation of the phagocyte-like NADPH oxidase (Nox2) leading to GSIS [6, 38, 39]. Based on compelling experimental evidence, it was concluded that Nox2 is one of the regulatory proteins involved in insulin secretion [6, 38, 39, 40, 41]. Rac1 is one of the components of the Nox2 holoenzyme, and it has been shown that Rac1 associates with other members of this holoenzyme upon GTP binding and activation [6, 30, 38]. Therefore, we propose that both Tiam1 and VAV2 serve as GEFs for Rac1 in mediating GSIS. It is noteworthy that pharmacological inhibition of both the Tiam1–Rac1 and VAV2–Rac1 pathways using NSC23766 and Ehop-016, respectively, yielded much greater inhibition of GSIS compared with inhibition of either of these pathways alone (ESM Fig. 4). These data indicate independent roles for these pathways (i.e. different downstream signalling events) in the induction of GSIS. Additional studies are needed to further validate this model. Liu and associates suggested novel regulation of Rac1 and redox signalling in response to fluid stress in endothelial cells . They reported the concerted actions of Tiam1 and VAV2 in linking components of the polarity complex (vascular endothelial–cadherin–neutrophil cytosol factor 2 [p67phox]–partitioning defective 3 homolog [Par3]) to the NADPH oxidase module. Data from these investigations suggest that VAV2 is required for GTP loading onto Rac1, whereas Tiam1 serves as an adaptor protein for the polarity complex, which directs the localised activation of Rac1. Thus, it is likely that the Tiam1/VAV2 module regulates GSIS at different levels via regulating distinct signalling steps.
Emerging evidence suggests that the regulation of Tiam1 and VAV2 functions by tyrosine phosphorylation is catalysed by SFKs. For example, using pharmacological and molecular biological approaches, Servitja and associates demonstrated regulatory roles for Tiam1 and VAV2 in Src-induced cell transformation via regulation of Rac1 activation . Earlier studies pointed out that phosphorylation of Vav on tyrosine residues [19, 20, 21, 22] activates its GEF activity [26, 27]. The phosphorylation step is mediated by the Vav structural domain (Src homology 2), which facilitates the interaction of Vav proteins with membrane and cytoplasmic tyrosine kinases [19, 20, 21, 22]. Our current studies demonstrate significant inhibition of glucose-induced VAV2 phosphorylation by SU6656. Indeed, recent investigations by Yoder et al  provide compelling evidence for YES tyrosine kinase activation as an early signalling event (∼1 min) involved in the activation of the small G protein Cdc42 (∼3 min) in glucose-stimulated islet beta cell. Likewise, studies of Garrett et al have demonstrated a requirement for tyrosine phosphorylation of VAV2 in vascular endothelial growth factor-induced Rac1 activation in endothelial cells . Together, these findings implicate a tyrosine phosphorylation step upstream to the activating GEFs (Tiam1/VAV2) for Rac1 activation and associated downstream signalling events. It is also likely that phosphorylation of VAV could be mediated via binding of the VAV2 pleckstrin homology domain region to biologically active lipid second messenger products of phosphatidylinositol-3-kinase  because these lipid second messengers are known to promote activation and translocation of Rac1 in beta cells . Future studies are needed to test these putative mechanisms to more precisely determine the molecular roles for the Tiam1/VAV2 axis in pancreatic beta cells.
Our current findings also suggest that VAV2-mediated Rac1 activation is important for actin cytoskeletal reorganisation and mobilisation of insulin granules towards the plasma membrane for their fusion and release. In the pancreatic beta cell, actin microfilaments juxtaposed to or beneath the plasma membrane are thought to restrict the localisation of secretory vesicles to release sites in the absence of stimulatory levels of glucose. Our data might suggest that VAV2–Rac1 binding is directly required for glucose-induced actin depolymerisation. Alternatively, these data may suggest that VAV2–Rac1 activation is downstream of events related to Cdc42 and PAK1 activation, both of which occur within the first 5 min of GSIS and are required for actin remodelling in the beta cell. Indeed, Cdc42 activation occurs downstream of YES kinase activation, an SFK-mediated tyrosine phosphorylation event. In conclusion, our findings provide the first evidence in real time for a VAV2–Rac1 signalling axis in actin cytoskeletal remodelling and GSIS in isolated beta cells, and form the basis for future investigations to precisely define the roles of this Tiam1/VAV2–Rac1 pathway in physiological insulin secretion in the islet.
We thank L. Philipson (University of Chicago, Chicago, IL, USA) for providing the LifeAct-GFP and C. Newgard, (Duke University Medical Center, Durham, NC, USA) for providing INS-1 832/13 cells.
This research was supported in part by a Merit Review award to AK (1I01BX002801) from the Department of Veterans Affairs and awards from the National Institutes of Health to AK (DK94201 and EY022230), DCT (DK67912 and DK102233) and from the JDRF to AK (5–2012–257) and DCT (17–2013–454). AK is also the recipient of a Senior Research Career Scientist Award from the Department of Veterans Affairs (13S-RCS-006). RT is the recipient of an American Heart Association pre-doctoral fellowship.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
AK, DCT, RV and CPV were responsible for the experimental plan, literature search, and manuscript writing and editing. DKA, RV, VS, RT and KS performed the experiments and analysed the data. RT, DKA, VS and KS also assisted AK in drafting the original manuscript and revising the article. All authors read and approved the final version of the manuscript. AK is responsible for the integrity of the work as a whole.
INS-1 832/13 cells were transfected with Life-Act GFP and 48 h post-transfection, cells were incubated (overnight) in the LS-LG RPMI-1640 medium in the presence of vehicle (DMSO). The following day, cells were pre-treated with vehicle in KRB for 1 h and F-actin remodeling in cells was imaged for up to 20 min after the addition of 20 mmol/l of glucose (AVI 109 kb)
- 37.Kowluru A, Veluthakal R, Rhodes CJ, Kamath V, Syed I et al (2010) Protein farnesylation-dependent Raf/extracellular signal-related kinase signaling links to cytoskeletal remodeling to facilitate glucose-induced insulin secretion in pancreatic beta-cells. Diabetes 59:967–977PubMedCentralCrossRefPubMedGoogle Scholar